查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983709

腫瘤體內CRO市場：依動物模型、給藥途徑、治療方法及最終用戶分類－2026年至2032年全球市場預測

Oncology Based In-Vivo CRO Market by Animal Model, Route Of Administration, Therapeutic Modality, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腫瘤領域的體內 CRO 市場價值將達到 15.7 億美元，到 2026 年將成長到 17.6 億美元，到 2032 年將達到 34.3 億美元，複合年成長率為 11.76%。

主要市場統計數據
基準年 2025 15.7億美元
預計年份：2026年 17.6億美元
預測年份 2032 34.3億美元
複合年成長率 (%) 11.76%

這凸顯了體內腫瘤學研究的策略必要性，以加速轉換突破，降低研發失敗率，並加強相關人員之間的臨床前決策。

腫瘤學研究領域依然複雜多變，這要求管理者需要簡潔明了、切實可行的洞察，以便做出直接影響後續臨床結果的臨床前決策。本執行摘要整合了營運、科學和策略觀點，旨在明確體內研究能力至關重要的領域、實驗設計選擇如何影響轉化意義，以及應指導服務和夥伴關係投資的組織優先事項。

在免疫工程、精確建模、整合分析和協作生態系統的驅動下，不斷發展的臨床前範式正在重塑腫瘤學體內研究的實踐。

臨床前研究環境正經歷一場變革，腫瘤學計畫的規劃和實施方式也隨之改變。免疫工程的進步以及人源化和基因定義的動物模型日益成熟，提高了實驗機制的精確度。同時，包括基於機器學習的影像分析和縱向生物標記追蹤在內的綜合分析方法，正在將複雜的體內資料集轉化為更清晰的「啟動/停止」訊號。這些技術進步也推動了組織架構的變革，例如藥物研發、轉換和臨床團隊之間更緊密的合作，以便更早就具有臨床意義的終點達成共識。

評估新的貿易壁壘對腫瘤體內服務提供和全球研究的持續性、營運、成本、監管和創新所產生的連鎖影響。

新的貿易政策和關稅體係正在產生一系列複雜的下游影響，遠不止於直接採購成本。前置作業時間、供應鏈碎片化和庫存持有成本增加。實際上，這些運作摩擦往往會導致研究啟動延遲、實驗週期縮短以及需要替代採購方式，所有這些都會降低腫瘤專案進度安排的可預測性。

透過分析模型選擇、給藥途徑、治療方法和最終用戶人口統計特徵，我們旨在揭示微妙的需求因素及其對體內腫瘤學實驗設計的影響。

穩健的細分觀點能夠清楚闡明科學和商業性優先事項的分歧所在，以及如何調整資源分配以契合實驗目標。在考慮動物模型時，研究通常分為小鼠模型和非小鼠模型。小鼠模型包括基因修飾小鼠模型、免疫原性同基因模型和小鼠異種移植模型，而非小鼠模型則包含犬、兔子和大鼠模型。每種模型在免疫學、藥理學和毒理學終點方面各有優勢，這直接指南研究設計決策和供應商選擇。因此，專案經理必須根據作用機制和所考慮的轉換挑戰來選擇合適的模型。

區域比較趨勢突顯了全球腫瘤研究中心明確的策略重點、供應鏈現狀、監管環境和合作研究機會。

區域趨勢影響著能力建構的發展方式、供應鏈的建構方式以及科學合作最活躍的領域。美洲地區匯聚了轉化醫學專長、強大的生物技術生態系統以及完善的免疫腫瘤學基礎設施，這有利於開展高通量、以轉化醫學為導向的體內研究項目，這些項目需要快速迭代並與臨床研發管線緊密結合。該地區對監管法規的熟悉程度以及活躍的創業投資活動，支持申辦方和服務供應商之間建立靈活的夥伴關係，同時也強調可重複性和文件記錄的重要性。

服務供應商之間的競爭定位和能力差異化，重點在於專業動物模型、技術整合、資訊服務和策略合作夥伴關係。

腫瘤生物醫學檢測領域的競爭格局日益取決於服務能力的廣度、專業知識的深度以及將資訊服務與實驗室運作相結合的能力。能夠同時擁有先進的小鼠模型、檢驗的非小鼠毒性測試平台以及嚴謹的給藥途徑專業知識的服務商，可以為轉化醫學計畫提供差異化的端到端解決方案。同樣重要的是，服務商還需具備滿足特定治療方式需求的能力，例如免疫查核點抑制劑的免疫治療終點檢測，以及激酶抑制劑和小分子藥物的藥物動力學和標靶結合檢測。

為高階主管提供可操作的策略建議，以建立業務永續營運、優先考慮科學投資並加速從臨床前腫瘤學計畫中創造轉化價值。

產業領導者應採取多管齊下的策略方法，在確保業務連續性的同時，充分利用科學進步。首先，應實現檢驗和庫存策略多元化，以減少對動物品系、特殊試劑和關鍵設備等單一故障點的依賴。確保擁有可靠的替代供應商，並維持關鍵組件的滾動庫存，即使在國際貿易或物流中斷的情況下，也能確保研究進度不受影響。其次，應優先投資於能反映治療重點領域的模型組合。例如，均衡地組合基因修飾小鼠模型、免疫原性同源模型和關鍵的非小鼠毒性模型，將確保能夠應對各種轉化醫學挑戰。

透過結合關鍵相關人員的資訊、實驗室檢驗、營運審計和精心挑選的第二手資料，採用穩健的三角測量方法，可以得出嚴謹且可操作的結論。

本執行報告的調查方法結合了定性一手調查、有針對性的營運檢驗和精心挑選的二手證據，確保研究結果嚴謹且具有直接適用性。一手資訊是透過對資深轉化科學研究人員、營運經理和採購專家進行結構化訪談收集的，旨在獲取關於模型選擇、供應商績效和物流挑戰的第一手觀點。除了訪談外，還進行營運審計和實驗室訪問，以檢驗工作流程、模型培育計劃和資料收集過程，從而對報告的能力進行現場確認。

透過整合營運洞察、科學趨勢和策略意義，得出明確的結論，從而指導經營團隊決策，並最佳化腫瘤學領域的短期研究計畫。

這項綜合分析凸顯了腫瘤學非臨床研究中的幾個永恆真理：模型選擇至關重要，運作韌性是轉化研究信心的基石，而整合的資料管理實踐則能縮短從實驗中觀察到專案決策的流程。免疫腫瘤學和標靶治療的科學進步需要針對個別情況最佳化的體內策略，這些策略應反映藥物的作用機制、給藥途徑和臨床終點。同時，從貿易措施到區域監管差異等外部壓力，正迫使申辦方和提供者投資於多元化的資源取得、在地化能力建設以及更完善的合約框架。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腫瘤學領域動物模型體內CRO市場

  • 老鼠
    • 基因改造小鼠模型
    • 具有免疫能力的相關譜系
    • 小鼠異種移植模型
  • 非滑鼠
    • 狗
    • 兔子
    • 鼠

第9章：腫瘤領域體內CRO市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：腫瘤治療方法體內CRO市場

  • 化療
  • 免疫療法
    • 查核點抑制劑
    • 單株抗體
  • 分子標靶治療
    • 激酶抑制劑
    • 小分子抑制劑

第11章：腫瘤體內CRO市場：依最終用戶分類

  • 學術機構和研究機構
  • CRO
  • 製藥公司

第12章：腫瘤領域體內CRO市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：腫瘤領域體內CRO市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：腫瘤領域體內CRO市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腫瘤領域體內CRO市場

第16章：中國腫瘤領域體內CRO市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bioanalytical Systems, Inc.
  • Celerion, Inc.
  • Champion Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Explora BioLabs, Inc.
  • Frontage Laboratories, Inc.
  • GenScript Biotech Corporation
  • GenScript ProBio Co., Ltd.
  • Inotiv, Inc.
  • JSR Life Sciences Corporation
  • KCR SA
  • Laboratory Corporation of America Holdings
  • Living Tumor Laboratory, Inc.
  • MPI Research, Inc.
  • Oncodesign SA
  • Parexel International Corporation
  • PRA Health Sciences, Inc.
  • Syneos Health, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory, Inc.
  • Toxikon Corporation
  • Translational Drug Development, Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-FF012EDC38C0

The Oncology Based In-Vivo CRO Market was valued at USD 1.57 billion in 2025 and is projected to grow to USD 1.76 billion in 2026, with a CAGR of 11.76%, reaching USD 3.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.57 billion
Estimated Year [2026] USD 1.76 billion
Forecast Year [2032] USD 3.43 billion
CAGR (%) 11.76%

Framing the strategic imperative for oncology in-vivo research to accelerate translational breakthroughs, reduce attrition, and strengthen preclinical decision-making across stakeholders

The landscape of oncology research remains complex and dynamic, and executives require concise, actionable intelligence to make preclinical decisions that directly influence downstream clinical outcomes. This executive summary synthesizes operational, scientific, and strategic perspectives to clarify where in-vivo capabilities matter most, how experimental design choices shape translational relevance, and which organizational priorities should guide investment in services and partnerships.

Throughout the report, emphasis is placed on the intersection between scientific rigor and operational resilience. Translational value depends not only on model selection and dosing paradigms but also on supply chain integrity, data fidelity, and regulatory alignment. Consequently, the executive view focuses on practical levers that reduce technical attrition, accelerate validation timelines, and improve reproducibility across multicenter programs. By concentrating on decision points that executives can influence-such as model portfolios, vendor qualification, and integrated data pipelines-this introduction sets the stage for a pragmatic, strategy-forward conversation that informs both near-term actions and medium-term capability building.

The intent is to equip decision-makers with a clear framework for aligning scientific priorities with commercial realities and operational constraints, thereby enabling more predictable and effective progression from preclinical insights to clinical hypotheses.

Evolving preclinical paradigms driven by immunoengineering, precision models, integrated analytics, and collaborative ecosystems that are reshaping oncology in-vivo research practices

The preclinical research environment has been undergoing transformative shifts that are changing how oncology programs are designed and executed. Advances in immunoengineering and the maturation of humanized and genetically defined animal models are improving the mechanistic fidelity of experiments. At the same time, integrated analytics, including machine learning-enabled image analysis and longitudinal biomarker tracking, are turning complex in-vivo datasets into clearer go/no-go signals. These technological evolutions are accompanied by organizational shifts: tighter collaboration between discovery, translational, and clinical teams is enabling earlier alignment on endpoints that matter clinically.

Concurrently, the industry is seeing methodological convergence between in-vivo and ex vivo approaches. Organoid systems and sophisticated co-culture platforms are increasingly used to triage candidates before committing to resource-intensive animal studies, thereby creating a cascade effect that raises the bar for the in-vivo experiments that are performed. Regulatory expectations and reproducibility imperatives are also prompting greater standardization of protocols and metadata capture, leading providers to invest in quality systems and data harmonization. Together, these shifts are not merely incremental; they are reshaping service offerings, partnership models, and the criteria by which translational success is judged.

Assessing the cascading operational, cost, regulatory, and innovation effects of emerging trade barriers on oncology in-vivo service delivery and global research continuity

Emerging trade policies and tariff regimes have introduced a complex set of downstream effects that extend beyond immediate procurement costs. Increased duties and customs scrutiny for imported reagents, specialized animal strains, and critical equipment can lead to longer lead times, fragmented supply chains, and higher inventory carrying costs. In practice, these operational frictions often translate into delayed study starts, compressed experiment windows, and the need for contingency sourcing, all of which erode schedule predictability for oncology programs.

Further, tariffs can alter vendor economics and sourcing decisions, prompting some providers to localize certain functions or to reconfigure service portfolios to rely less on imported components. This reconfiguration can have knock-on effects for model availability, especially for specialized or proprietary strains that are produced in geographically concentrated facilities. In turn, sponsors and service providers face a choice between maintaining tight biological fidelity through original model use or accepting alternative models that may introduce translational risk.

Importantly, the cumulative impact of trade measures also affects collaborative research that depends on cross-border sample transfers or multinational study coordination. To maintain momentum, research leaders must prioritize supply chain transparency, diversify vendor relationships, and incorporate contingency planning into project timelines. When combined with improved forecasting and contractual flexibility, such measures help mitigate the operational uncertainty introduced by evolving tariff environments.

Dissecting model selection, administration routes, therapeutic modalities, and end user segmentation to reveal nuanced demand drivers and experimental design implications for in-vivo oncology

A robust segmentation lens clarifies where scientific and commercial priorities diverge, and how resource allocation should be tailored to experimental intent. When examined by animal model, studies are commonly categorized into murine and non-murine groups; murine models include genetically engineered mouse models, immunocompetent syngeneic models, and mouse xenografts, while non-murine options encompass dog, rabbit, and rat models. Each of these model classes has different strengths for immunology, pharmacology, and toxicology endpoints, which directly guides study design decisions and vendor selection. Thus, portfolio managers should align model choice with the mechanism of action and the translational questions at hand.

Route of administration segmentation-typically intravenous, oral, and subcutaneous-further refines experimental planning. Dosing route influences pharmacokinetics, formulation strategies, and safety assessment, and therefore it must be considered early in preclinical development to ensure clinically relevant exposure. Therapeutic modality segmentation delineates distinct developmental pathways: chemotherapy, immunotherapy, and targeted therapy; within immunotherapy, checkpoint inhibitors and monoclonal antibodies are principal subcategories, and within targeted therapy, kinase inhibitors and small molecule inhibitors define technical approaches. These modality distinctions have operational implications for dosing regimens, biomarker selection, and model suitability.

Finally, end user segmentation-covering academia and research institutes, contract research organizations, and pharmaceutical companies-reveals differing expectations around throughput, documentation rigor, and customization. Academic customers often prioritize exploratory endpoints and method development, whereas pharmaceutical sponsors emphasize regulatory readiness and data traceability. Contract research organizations occupy an intermediary role, balancing standardization with bespoke services to serve both academic and industry clients. Together, these segmentation dimensions create a matrix that should inform capability investments, pricing strategies, and partnership models.

Comparative regional dynamics highlighting distinct strategic priorities, supply chain realities, regulatory landscapes, and collaborative opportunities across global oncology research hubs

Regional dynamics shape how capabilities are developed, how supply chains are structured, and where scientific collaboration is most active. In the Americas, there is a concentration of translational expertise, strong biotech ecosystems, and established infrastructure for immuno-oncology, which encourages high-throughput, translationally focused in-vivo programs that demand rapid iteration and close integration with clinical pipelines. This region's regulatory familiarity and dense venture capital activity support agile partnerships between sponsors and service providers, yet it also places a premium on reproducibility and documentation practices.

In Europe, Middle East & Africa, variations in regulatory frameworks and research funding models create heterogeneity in capability and demand. Institutional collaborations and multi-center academic networks often drive innovation here, and providers frequently need to accommodate a broader spectrum of compliance requirements and language-specific documentation. Supply chain considerations can vary significantly across countries, making regional logistics expertise and local inventory strategies important for maintaining timelines.

Asia-Pacific is characterized by fast-growing research capacity, increasing domestic pharmaceutical R&D, and a rising share of outsourced preclinical work. This region offers opportunities for cost-effective operations, access to diverse biological models, and expanding laboratory infrastructure. However, leaders must navigate differing regulatory expectations, local ethical standards, and the need for robust quality management systems to ensure data generated locally is acceptable to multinational sponsors. Altogether, regional distinctions influence how providers prioritize investments and how sponsors allocate studies to maximize both scientific validity and operational efficiency.

Competitive positioning and capability differentiation among service providers emphasizing specialized animal models, technology integration, data services, and strategic alliances

Competitive dynamics in the oncology in-vivo space are increasingly defined by capability breadth, specialization depth, and the ability to integrate data services with wet-lab operations. Providers that combine access to advanced murine models, validated non-murine toxicology platforms, and rigorous route-of-administration expertise can offer differentiated end-to-end solutions for translational programs. Equally important is the capacity to support modality-specific needs, such as immunotherapy endpoint assays for checkpoint inhibitors or pharmacokinetic and target engagement assays for kinase inhibitors and small molecule programs.

Beyond technical offerings, leading firms are investing in standardized reporting, electronic data capture, and analytics platforms that translate raw experimental outputs into decision-ready intelligence. Strategic alliances and co-development arrangements with discovery organizations are also shaping the competitive landscape, enabling providers to participate earlier in candidate selection and to influence preclinical strategy. Service differentiation is furthermore influenced by geographical reach and supply chain robustness; providers with localized breeding facilities, decentralized reagent sourcing, and clear export/import expertise are more resilient to operational shocks.

Intellectual property considerations and the emergence of specialized contract service verticals-such as immuno-oncology platforms or precision oncology models-create niches that smaller, highly specialized providers can exploit. For sponsors, selecting a partner increasingly involves assessing both technical fit and the provider's ability to adapt protocols, share data transparently, and align around development timelines.

Actionable strategic recommendations for leaders to build operational resilience, prioritize scientific investments, and accelerate translational value from preclinical oncology programs

Industry leaders should adopt a multi-pronged strategic approach to capitalize on scientific advances while safeguarding operational continuity. First, diversify sourcing and inventory strategies to reduce exposure to single-point failures in animal strains, specialized reagents, and critical equipment. Building validated alternative suppliers and maintaining rolling inventory for key components will preserve study schedules when external trade or logistics disruptions occur. Second, prioritize investment in model portfolios that reflect therapeutic focus areas; for example, retain a balanced mix of genetically engineered mouse models, immunocompetent syngeneic systems, and key non-murine toxicology models to cover a broad spectrum of translational questions.

Third, integrate data management and analytics capabilities with laboratory operations to ensure high-quality metadata capture, reproducible protocols, and rapid downstream analysis. Establishing common data standards across internal and external partners reduces ambiguity in interpretation and accelerates decision cycles. Fourth, engage proactively with regulatory and ethical bodies to harmonize expectations for study design, humane use of animals, and data transparency; early engagement mitigates rework and supports cross-border acceptability of data. Finally, invest in talent development and cross-functional teams that bridge discovery, translational science, and operations so that experimental design decisions are aligned with program objectives and commercial imperatives.

Taken together, these measures create a resilient, scientifically robust platform that supports faster, more reliable translation of preclinical findings into clinical investigation.

Robust triangulation approach combining primary stakeholder intelligence, laboratory validations, operational audits, and curated secondary evidence to ensure rigorous actionable conclusions

The research methodology underpinning this executive synthesis combines qualitative primary engagement, targeted operational validation, and curated secondary evidence to ensure findings are both rigorous and directly applicable. Primary inputs included structured interviews with senior translational scientists, operational leaders, and procurement specialists to capture first-hand perspectives on model selection, vendor performance, and logistics challenges. These interviews were complemented by operational audits and lab visits that validated workflows, model breeding programs, and data capture processes, providing on-the-ground confirmation of reported capabilities.

Secondary evidence was assembled from open literature, technical white papers, and regulatory guidance documents to contextualize technological trends and evolving best practices. To ensure reliability, findings were triangulated across multiple sources and checked for internal consistency; where divergent perspectives emerged, follow-up queries were used to reconcile differences and to clarify the operational implications. Quality control procedures included protocol traceability checks, verification of assay validation status, and assessment of data management practices to confirm reproducibility claims.

By combining stakeholder insight with empirical validation and documentary review, the methodology balances depth and breadth, resulting in conclusions that are both evidence-based and pragmatic for decision-makers.

Clear conclusions synthesizing operational insights, scientific trends, and strategic implications to guide executive decision-making and near term research program optimization in oncology

This synthesis brings into focus several enduring truths for preclinical oncology research: model choice matters, operational resilience underwrites translational confidence, and integrated data practices shorten the path from experimental observation to program decision. Scientific progress in immuno-oncology and targeted therapeutics demands tailored in-vivo strategies that reflect mechanism of action, dosing route, and clinical endpoints. At the same time, external pressures-ranging from trade measures to regional regulatory variation-require that sponsors and providers alike invest in diversified sourcing, localized capabilities, and stronger contractual frameworks.

Looking ahead, organizations that harmonize scientific rigor with operational discipline will be best positioned to de-risk early development and to deliver reproducible, clinically meaningful data. This requires a sustained focus on capability building, cross-functional alignment, and strategic partnerships that enable earlier access to translational expertise. Ultimately, the combination of advanced model systems, robust quality systems, and analytics that produce decision-ready outputs will determine which programs advance with confidence and which require further iteration.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Based In-Vivo CRO Market, by Animal Model

  • 8.1. Murine
    • 8.1.1. Genetically Engineered Mouse Model
    • 8.1.2. Immunocompetent Syngeneic
    • 8.1.3. Mouse Xenograft
  • 8.2. Non Murine
    • 8.2.1. Dog
    • 8.2.2. Rabbit
    • 8.2.3. Rat

9. Oncology Based In-Vivo CRO Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Oncology Based In-Vivo CRO Market, by Therapeutic Modality

  • 10.1. Chemotherapy
  • 10.2. Immunotherapy
    • 10.2.1. Checkpoint Inhibitors
    • 10.2.2. Monoclonal Antibodies
  • 10.3. Targeted Therapy
    • 10.3.1. Kinase Inhibitors
    • 10.3.2. Small Molecule Inhibitors

11. Oncology Based In-Vivo CRO Market, by End User

  • 11.1. Academia & Research Institute
  • 11.2. Contract Research Organization
  • 11.3. Pharmaceutical

12. Oncology Based In-Vivo CRO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncology Based In-Vivo CRO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncology Based In-Vivo CRO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oncology Based In-Vivo CRO Market

16. China Oncology Based In-Vivo CRO Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bioanalytical Systems, Inc.
  • 17.6. Celerion, Inc.
  • 17.7. Champion Oncology, Inc.
  • 17.8. Charles River Laboratories International, Inc.
  • 17.9. Crown Bioscience, Inc.
  • 17.10. Explora BioLabs, Inc.
  • 17.11. Frontage Laboratories, Inc.
  • 17.12. GenScript Biotech Corporation
  • 17.13. GenScript ProBio Co., Ltd.
  • 17.14. Inotiv, Inc.
  • 17.15. JSR Life Sciences Corporation
  • 17.16. KCR S.A.
  • 17.17. Laboratory Corporation of America Holdings
  • 17.18. Living Tumor Laboratory, Inc.
  • 17.19. MPI Research, Inc.
  • 17.20. Oncodesign SA
  • 17.21. Parexel International Corporation
  • 17.22. PRA Health Sciences, Inc.
  • 17.23. Syneos Health, Inc.
  • 17.24. Taconic Biosciences, Inc.
  • 17.25. The Jackson Laboratory, Inc.
  • 17.26. Toxikon Corporation
  • 17.27. Translational Drug Development, Inc.
  • 17.28. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)